Prasugrel and ticagrelor: Equally safe and effective in STEMI

The antiplatelet drugs prasugrel and ticagrelor had similar safety and efficacy among patients with acute myocardial infarction and ST segment elevations (STEMI), according to results of PRAGUE-18, the first randomised, head-to-head comparison of the drugs.

"Our findings confirm previous indirect - non-randomized- comparisons of these two drugs, based on analyses of various registries," commented Petr Widimsky MD, DrSc, from the Cardiocenter of Charles University, in Prague, Czech Republic. "Thus, both drugs are very effective and safe and significantly contribute to the excellent outcomes of patients with in modern cardiology."

The Hot Line study, presented at ESC Congress 2016, randomized 1,230 STEMI patients to receive either prasugrel or ticagrelor prior to primary (pPCI).

The primary end-point was defined as death, re-infarction, urgent target vessel revascularization, stroke, serious bleeding requiring transfusion, or prolonged hospitalization at 7 days.

The trial was halted prematurely after an interim analysis showed no difference in the rate of this endpoint between groups (4.0% and 4.1% in the prasugrel and ticagrelor groups, respectively; P=0.939).

There was also no difference between groups in the rate of the key secondary end-point, composed of cardiovascular death, non-fatal or stroke within 30 days (2.7% and 2.5%, respectively; P=0.864).

"These study results offer more freedom to clinicians to select the antiplatelet agent added on top of aspirin for patients with STEMI who receive dual antiplatelet therapy," commented Prof. Widimsky.

Final follow-up will be at 1 year for all patients, and will be completed in 2017.

The PRAGUE acronym refers to a series of academic randomized trials coordinated by the Cardiocenter, Charles University Prague, starting with PRimary Angioplasty in with myocardial infarction transferred from General community hospitals to angioplasty Units of tertiary cardiology centers with or without Emergency thrombolysis (2000).


Explore further

ANTARCTIC trial antiplatelet monitoring: No benefit in elderly patients

Citation: Prasugrel and ticagrelor: Equally safe and effective in STEMI (2016, August 30) retrieved 20 June 2019 from https://medicalxpress.com/news/2016-08-prasugrel-ticagrelor-equally-safe-effective.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
0 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more